A Open-Label Ascending Dose Study to Evaluate the Safety and Effects of PR001A in Patients With Parkinson's Disease
Recruiting
35-80 years
All
Phase
1
12 participants needed
1 Location
Brief description of study
This is a 5 year study and the purpose is to assess the safety and tolerability of 2 dose levels of PR001A administered via l injection in patients with moderate to severe Parkinson's Disease
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Parkinson's Disease
-
Age: Between 35 Years - 80 Years
-
Gender: All
Male or Female Age 35-80 (BMI) of 18 to 34 Diagnosis of Parkinson's Disease
Updated on
01 Aug 2024.
Study ID: 843759
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
